Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies
The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F FPM for finding sites of malignancies.
Squamous Cell Carcinoma
RADIATION: 18F FPM
Safety of D-18F FPM and L-18F FPM administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F FPM administration, Up to 28 days following 18F FPM administration (+/- 7 days)
Percentage of injected D-18F FPM and L-18F FPM dose in organs of interest., 10, 30, 60 and 120 minutes post 18F FPM administration|Percentage of unmetabolized D-18F FPM and L-18F FPM in plasma and urine after radiotracer administration., 30 (plasma only) and 90 (plasma and urine) minutes post 18F FPM administration|Absorbed organ doses expressed as micro Sv/MBq of administered D-18F FPM and L-18F FPM, and whole body dose expressed as milliSv/200MBq of administered dose, 10, 30, 60 and 120 minutes post 18F FPM administration
The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F FPM for finding sites of malignancies.